Last reviewed · How we verify
Tegafur gimeracil oteracil potassium capsule
At a glance
| Generic name | Tegafur gimeracil oteracil potassium capsule |
|---|---|
| Also known as | TS-1 |
| Sponsor | Yu jiren |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ (PHASE2)
- Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ (PHASE2)
- A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10 (PHASE2)
- Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer (PHASE3)
- Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer (PHASE2)
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study (PHASE2)
- Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer (PHASE2)
- Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegafur gimeracil oteracil potassium capsule CI brief — competitive landscape report
- Tegafur gimeracil oteracil potassium capsule updates RSS · CI watch RSS
- Yu jiren portfolio CI